EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AAV-Mediated Targeting of the Activin A-ACVR1R206H Signaling in Fibrodysplasia Ossificans Progressiva

Yeon-Suk Yang, Chujiao Lin, Hong Ma, Jun Xie, Frederick S Kaplan, Guangping Gao, Jae-Hyuck Shim iD

Biomolecules · 2023

DOI: 10.3390/biom13091364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Yeon-Suk Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA. Hauptthemen laut MEDLINE: Activin Receptors, Type I, Myositis Ossificans. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIAMS NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder characterized by progressive disabling heterotopic ossification (HO) at extra-skeletal sites. Here, we developed adeno-associated virus (AAV)-based gene therapy that suppresses trauma-induced HO in FOP mice harboring a heterozygous allele of human ACVR1R206H (Acvr1R206H/+) while limiting the expression in non-skeletal organs such as the brain, heart, lung, liver, and kidney. AAV gene therapy carrying the combination of codon-optimized human ACVR1 (ACVR1opt) and artificial miRNAs targeting Activin A and its receptor ACVR1R206H ablated the aberrant activation of BMP-Smad1/5 signaling and the osteogenic differentiation of Acvr1R206H/+ skeletal progenitors. The local delivery of AAV gene therapy to HO-causing cells in the skeletal muscle resulted in a significant decrease in endochondral bone formation in Acvr1R206H/+ mice. These mice showed little to no expression in a major AAV-targeted organ, the liver, due to liver-abundant miR-122-mediated repression. Thus, AAV gene therapy is a promising therapeutic strategy to explore in suppressing HO in FOP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Activin Receptors, Type IMyositis OssificansAnimalsHumansMiceActivinsDependovirusOsteogenesis

Stichwörter der Autor:innen

AAVACVR1Activin Afibrodysplasia ossificans progressivagene therapyheterotopic ossificans

Substanzen

activin AActivin Receptors, Type IActivinsACVR1 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
  • Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
  • Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
  • Viral Vector Core, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
  • Department of Orthopaedic Surgery, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Medicine, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.

ORCID-Profile: Jae-Hyuck Shim

Förderung

  • NIAID NIH HHS
  • NIAMS NIH HHS
  • NICHD NIH HHS
  • NINDS NIH HHS
  • NIH
  • NIH/NIAMS
  • International FOP Association, and AAVAA Therapeutics
  • Isaac & Rose Nassau Professorship of Orthopedic Molecular Medicine

Zitieren

APA

Yang, Y. S., Lin, C., Ma, H., Xie, J., Kaplan, F. S., Gao, G., & Shim, J. H. (2023). AAV-Mediated Targeting of the Activin A-ACVR1R206H Signaling in Fibrodysplasia Ossificans Progressiva. Biomolecules. https://doi.org/10.3390/biom13091364

Vancouver

Yang YS, Lin C, Ma H, Xie J, Kaplan FS, Gao G, et al. AAV-Mediated Targeting of the Activin A-ACVR1R206H Signaling in Fibrodysplasia Ossificans Progressiva. Biomolecules. 2023. doi:10.3390/biom13091364

BibTeX
@article{Yang2023,
  author = {Yang, Yeon-Suk and Lin, Chujiao and Ma, Hong and Xie, Jun and Kaplan, Frederick S and Gao, Guangping and Shim, Jae-Hyuck},
  title = {AAV-Mediated Targeting of the Activin A-ACVR1R206H Signaling in Fibrodysplasia Ossificans Progressiva},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13091364}
}
Kostenlos starten →